Colorectal Cancer Screening Tests Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Summary
GlobalData's Medical Devices sector report, “Colorectal Cancer Screening Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Colorectal Cancer Screening Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Colorectal Cancer Screening Tests includes Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits and Other Colorectal Cancer Screening Tests.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Colorectal Cancer Screening Tests under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Colorectal Cancer Screening Tests and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Colorectal Cancer Screening Tests under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Colorectal Cancer Screening Tests Overview
4 Products under Development
4.1 Colorectal Cancer Screening Tests - Pipeline Products by Stage of Development
4.2 Colorectal Cancer Screening Tests - Pipeline Products by Segment
4.3 Colorectal Cancer Screening Tests - Pipeline Products by Territory
4.4 Colorectal Cancer Screening Tests - Pipeline Products by Regulatory Path
4.5 Colorectal Cancer Screening Tests - Pipeline Products by Estimated Approval Date
4.6 Colorectal Cancer Screening Tests - Ongoing Clinical Trials
5 Colorectal Cancer Screening Tests - Pipeline Products under Development by Companies
5.1 Colorectal Cancer Screening Tests Companies - Pipeline Products by Stage of Development
5.2 Colorectal Cancer Screening Tests – Companies Pipeline Products by Stage of Development
6 Colorectal Cancer Screening Tests Companies and Product Overview
7 Colorectal Cancer Screening Tests- Recent Developments
7.1 Nov 17, 2023: Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
7.2 Nov 15, 2023: Geneoscopy and Labcorp sign deal for colorectal cancer screening test
7.3 Nov 14, 2023: Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
7.4 Nov 12, 2023: Guardant Health Launches Shield Blood-Based Screening Test for Colorectal Cancer In South Korea
7.5 Nov 09, 2023: Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
7.6 Nov 07, 2023: Mainz Biomed to Showcase ColoAlert at Leading Global Healthcare Event, MEDICA
7.7 Nov 02, 2023: 2San Receives CLIA Approval For One Step Immunochemical Fecal Occult Blood Test (iFOB)
7.8 Nov 02, 2023: Zydus and Guardant Health to Jointly Promote the GUARDANT360 Portfolio of Nextgeneration Genomic Tests for Advanced Solid Cancers in India and Nepal
7.9 Oct 19, 2023: Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
7.1 Oct 18, 2023: Mainz Biomed Presents Groundbreaking Results of Colofuture Study
7.11 Oct 11, 2023: Mainz Biomed to Showcase ColoAlert at UEG Week 2023 in Copenhagen, Denmark
7.12 Oct 09, 2023: Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
7.13 Oct 04, 2023: Mainz Biomed Announces Live Launch of ColoAlert with Bioclinica in Romania
7.14 Sep 27, 2023: Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
7.15 Sep 25, 2023: Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
7.16 Sep 13, 2023: Mainz Biomed looks to expand cancer identification list for ColoAlert
7.17 Sep 05, 2023: Mainz Biomed Announces Strategic Partnership With ÄRztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
7.18 Aug 29, 2023: Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
7.19 Aug 28, 2023: Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
7.2 Aug 22, 2023: Mainz Biomed Announces Live Launch of ColoAlert with testDNA Laboratory in Poland
7.21 Aug 14, 2023: Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO
7.22 Aug 03, 2023: CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect Colorectal Disease Screening Test
7.23 Aug 01, 2023: Mainz Biomed Announces Live Launch of ColoAlert with Marylebone Laboratory in the United Kingdom
7.24 Jul 06, 2023: iCellate Medical Discontinues Direct-To-Consumer Sales of Its GeneMate service
7.25 Jul 03, 2023: Rhythm Establishes UK subsidiary for Market Entry
7.26 Jun 29, 2023: Mainz Biomed Secures up to $50M in New Funding
7.27 Jun 28, 2023: Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
7.28 Jun 20, 2023: Mainz Biomed Expands into Romania Through Partnership with Bioclinica
7.29 Jun 08, 2023: iCellate Medical Secures 20 MSEK in New Funding
7.3 Jun 06, 2023: Abstract & Poster Highlighting Positive Clinical Results For Colostat Poster Presentation at ASCO Annual Meeting
7.31 May 31, 2023: Mainz Biomed expands commercial footprint into Poland
7.32 May 25, 2023: Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
7.33 May 24, 2023: Mainz Biomed processes first patients from colorectal cancer Screening campaign through its corporate health portal in partnership with Zoeller-Kipper
7.34 May 24, 2023: Executes a UK strategic partnership with LINK Medical Solutions
7.35 May 18, 2023: CK Life Sciences Int'l (Holdings) announces poll results at annual general meeting
7.36 May 17, 2023: Exact Sciences awards grants to 18 organizations focused on increasing colorectal cancer screenings
7.37 May 17, 2023: UKCA mark granted for ColoSTAT
7.38 May 09, 2023: Invitae reports Q1 2023 financial results
7.39 May 04, 2023: BCAL Diagnostics opens new laboratory in sydney as it accelerates development of its breast cancer blood screening tool
7.4 May 03, 2023: Mainz Biomed announces addition of Eurofins GeLaMed to its growing network of lab partners
7.41 May 01, 2023: Mainz Biomed to participate in Digestive Disease Week 2023
7.42 Apr 26, 2023: Mainz Biomed announces partnership with the Instituto de Microecologia to expand ColoAlert commercialization in Spain and Portugal
7.43 Apr 26, 2023: Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023
7.44 Apr 24, 2023: Salix Partners with the Colorectal Cancer Alliance on community screening program
7.45 Apr 21, 2023: Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
7.46 Apr 20, 2023: Bescreened blood-based colorectal cancer test available at any lab test now locations across the country
7.47 Apr 16, 2023: DiaCarta announces five abstracts accepted for presentation at AACR Annual Meeting 2023
7.48 Apr 06, 2023: ColoSTAT abstract accepted for presentation at 2023 ASCO Annual Meeting
7.49 Apr 04, 2023: Mainz Biomed expands corporate health program for ColoAlert with the addition of Three new companies in Germany
7.5 Apr 03, 2023: Labcorp Expands Access to Colorectal Cancer Screening Through Partnership with the Conference of National Black Churches
7.51 Mar 29, 2023: BGI Genomics partners with Zentya to launch fecal DNA test for colorectal cancer in Slovakia
7.52 Mar 29, 2023: Mainz Biomed reports positive results from feasibility study evaluating its portfolio of novel mRNA biomarkers for early detection of advanced colorectal adenomas
7.53 Mar 23, 2023: $3.3 million grant to IU researchers aims to increase colorectal cancer screening in rural Indiana
7.54 Mar 21, 2023: Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
7.55 Mar 21, 2023: QuikRead go iFOBT is a quantitative feacal test for detecting excess gastrointestinal bleeding
7.56 Mar 15, 2023: BeScreened blood-based colorectal cancer test provides affordable early detection and without the mess
7.57 Mar 15, 2023: Mainz Biomed announces partnership with Labor Staber to expand ColoAlert commercialization in Germany
7.58 Mar 13, 2023: Guardant Health seeks US FDA premarket approval for CRC screening test
7.59 Mar 06, 2023: Rhythm Biosciences : Update to TGA Submission for ColoSTAT Test-Kit
7.6 Mar 02, 2023: Smiths Detection and GRASP innovations to collaborate on technology integration
7.61 Feb 15, 2023: Guardant Health initiates new study to examine the impact of Shield blood test to increase screening compliance for colorectal cancer
7.62 Feb 15, 2023: Mainz Biomed expands European commercial footprint and enters markets in Spain and UK
7.63 Feb 15, 2023: Rhythm maintains ISO certification
7.64 Feb 07, 2023: BGI COLOTECT 3.0 demonstrates higher colorectal cancer detection sensitivity than FIT
7.65 Jan 31, 2023: Guardant360 CDx gets FDA approval as companion diagnostic for ORSERDU
7.66 Jan 24, 2023: Geneoscopy submits premarket approval application to U.S. Food and Drug Administration for its noninvasive Colorectal Cancer RNA Biomarker Screening Test
7.67 Jan 18, 2023: Mainz Biomed launches corporate health program in Germany for ColoAlert
7.68 Jan 09, 2023: Foundation Medicine and Natera announce the launch of FoundationOneTracker personalized circulating tumor DNA monitoring assay for investigational use and early access clinical use
7.69 Dec 20, 2022: Mainz Biomed enrolls first patient in eAArly DETECT study evaluating integration of novel mRNA biomarkers into ColoAlert
7.7 Dec 15, 2022: Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
7.71 Dec 14, 2022: Epigenomics releases performance data on Next Generation test
7.72 Dec 08, 2022: Biomerica receives KFDA and Ministry of Health approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
7.73 Dec 06, 2022: Mainz Biomed announces IRB approval and initiation of US pivotal FDA clinical study
7.74 Nov 29, 2022: BGI preparing to launch improved non-invasive colorectal cancer screening test, COLOTECT 3.0
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
2.1 List of Tables
Table 1: Colorectal Cancer Screening Tests - Pipeline Products by Stage of Development
Table 2: Colorectal Cancer Screening Tests - Pipeline Products by Segment
Table 3: Colorectal Cancer Screening Tests - Pipeline Products by Territory
Table 4: Colorectal Cancer Screening Tests - Pipeline Products by Regulatory Path
Table 5: Colorectal Cancer Screening Tests - Pipeline Products by Estimated Approval Date
Table 6: Colorectal Cancer Screening Tests - Ongoing Clinical Trials
Table 7: Colorectal Cancer Screening Tests Companies - Pipeline Products by Stage of Development
Table 8: Colorectal Cancer Screening Tests – Companies Pipeline Products by Stage of Development
Table 75: Next-Generation Colorectal Cancer Test - Prospective, Multi-center Observational Study for the Clinical Validation of the Next Generation Test for Blood-based Screening of Colorectal Cancer
Table 80: Circulating Tumor DNA Test - Colorectal Cancer - Clinical Validation Study of Circulating Tumor DNA Test to Detect Minimal Residual Disease in Patients with Colorectal Cancer: CORRECT-MRD II
Table 81: Circulating Tumor DNA Test - Colorectal Cancer - CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Table 82: Foundation Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 92: Multi-Target Stool RNA (Mt-sRNA) Biomarker Panel - Clinical Validation of the ColonoSight Test: A Multi-target Stool RNA (Mt-sRNA) Assay for Colorectal Neoplasia Screening in Average-risk Individuals Aged More Than 45 Years Old
Table 103: Guardant Shield IVD-CRC Test - Product Status 5
Table 104: Guardant Shield IVD-CRC Test - Product Description 5
Table 105: Guardant360 Liquid Biopsy Test - Product Status
Table 106: Guardant360 Liquid Biopsy Test - Product Description
Table 107: LUNAR-2 Assay - Product Status
Table 108: LUNAR-2 Assay - Product Description
Table 109: Guardant Health Inc - Ongoing Clinical Trials Overview
Table 110: LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Table 111: Guardant Shield IVD-CRC Test - Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice in the Outpatient Clinical Settings in the Appalachian Highlands
Table 112: Guardant Shield IVD-CRC Test - The Ohio State University Guardant Shield Colorectal Cancer Screening Project
Table 113: Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
Table 130: Next Generation AA/CRC Screening Test - A Study to Evaluate the Integration of a Portfolio of Novel Gene Expression (mRNA) Biomarkers into ColoAlert 5
Table 131: Next Generation AA/CRC Screening Test - Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for the Detection of Colorectal Cancer and Advanced Adenoma in an Average Risk Population 5
Table 132: Next Generation AA/CRC Screening Test - Validity and Diagnostic Performance of an Optimized Multi-target Stool Nucleic Acid Test Combined with FIT (ColoAlert 3.0) For Early Detection of Colorectal Cancer and Advanced Precancerous Lesions in Colon 5